Real-World Data Show SGLT2 Inhibitors for Diabetes Triple DKA Risk Real-World Data Show SGLT2 Inhibitors for Diabetes Triple DKA Risk

Finding appears to be a class effect; drugs are also increasingly being used by cardiologists and nephrologists, so it ' s important they know about this rare but serious side effect.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news